Diabetes drug shows promise in protecting kidneys from damage

NCT ID NCT03436693

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

Summary

This study tested whether the diabetes medication canagliflozin could slow the progression of kidney disease in people with diabetes. It involved 308 Japanese patients who already had signs of kidney damage and were taking standard blood pressure medications. Researchers compared canagliflozin against a placebo over two years to see which group better preserved kidney function.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research site

Aichi, Japan
Research site

Chiba, Japan
Research site

Fukuoka, Japan
Research site

Fukushima, Japan
Research site

Gunma, Japan
Research site

Hiroshima, Japan
Research site

Hokkaido, Japan
Research site

Hyōgo, Japan
Research site

Ibaraki, Japan
Research site

Kagawa, Japan
Research site

Kagoshima, Japan
Research site

Kanagawa, Japan
Research site

Kumamoto, Japan
Research site

Mie, Japan
Research site

Nagano, Japan
Research site

Nagasaki, Japan
Research site

Okinawa, Japan
Research site

Osaka, Japan
Research site

Ōita, Japan
Research site

Saitama, Japan
Research site

Shizuoka, Japan
Research site

Tochigi, Japan
Research site

Tokyo, Japan
Research site

Wakayama, Japan
Research site

Yamagata, Japan
Research site

Yamaguchi, Japan

Conditions

Explore the condition pages connected to this study.

DIABETIC NEPHROPATHY